Skip to main content
Erschienen in:

31.10.2020 | Original Article

Efficacy and Safety of Diethylcarbamazine in Treatment of Allergic Rhinitis: A Double Blind Randomised Controlled Trial

verfasst von: S. Mohana Karthikeyan, G. N. Nikisha

Erschienen in: Indian Journal of Otolaryngology and Head & Neck Surgery | Sonderheft 2/2022

Einloggen, um Zugang zu erhalten

Abstract

There are many evidences showing diethylcarbamazine as a potential drug for the treatment of allergic rhinitis. This study evaluated the effectiveness of diethylcarbamazine in the treatment of allergic rhinitis and compared it with montelukast and levocetirizine. This parallel double-blind randomized clinical trial was done in allergic rhinitis patients. Seven hundred and twelve participants who met the inclusion criteria and provided informed written consent were randomized and divided into 2 equal groups. Diethylcarbamazine 300 mg/day orally in divided doses was given to group A, and montelukast 10 mg and levocetirizine 5 mg/day orally at night for 21 days was given to group B. Primary outcomes were the change in symptoms, absolute eosinophil count, serum total IgE, phadiatop and response in skin prick from baseline to 21 days and 3 months after treatment. Secondary outcome was to compare it with montelukast and levocetirizine. The mean (SD) age of the patients was 33 (10.6) years, with 374 (52.5%) males and 338 (47.5%) females. There was statistically significant improvement in all the parameters in both groups. Improvement was better with diethylcarbamazine compared to montelukast and levocetirizine and the effects were sustained for 3 months in diethylcarbamazine group. The findings suggest that diethylcarbamazine is effective in the treatment of allergic rhinitis. It gives better control and is cost-effective than montelukast and levocetirizine.
Trial Registration: https://​www.​ctri.​nic.​in Identifier: CTRI/2020/03/024145 registered on 20-03-2020.
Literatur
1.
Zurück zum Zitat Strachan D, Sibbald B, Weiland S et al (1997) Worldwide variations in prevalence of symptoms of allergic rhinoconjunctivitis in children: the international study of asthma and allergies in childhood (ISAAC). Pediatr Allergy Immunol 8:161–176PubMed Strachan D, Sibbald B, Weiland S et al (1997) Worldwide variations in prevalence of symptoms of allergic rhinoconjunctivitis in children: the international study of asthma and allergies in childhood (ISAAC). Pediatr Allergy Immunol 8:161–176PubMed
2.
Zurück zum Zitat Amin K, Issa SM, Ali KM et al (2020) Evidence for eosinophil and IL-17 mediated inflammation in allergic rhinitis. Clin Mol Allergy 18:1–7 Amin K, Issa SM, Ali KM et al (2020) Evidence for eosinophil and IL-17 mediated inflammation in allergic rhinitis. Clin Mol Allergy 18:1–7
3.
Zurück zum Zitat Charlesworth EN, Hood AF, Soter NA, Kagey-Sobotka A, Norman PS, Lichtenstein LM (1989) Cutaneous late-phase response to allergen: mediator release and inflammatory cell infiltration. J Clin Invest 83(5):1519–1526PubMedPubMedCentral Charlesworth EN, Hood AF, Soter NA, Kagey-Sobotka A, Norman PS, Lichtenstein LM (1989) Cutaneous late-phase response to allergen: mediator release and inflammatory cell infiltration. J Clin Invest 83(5):1519–1526PubMedPubMedCentral
4.
Zurück zum Zitat Wenzel S, Wilbraham D, Fuller R, Getz EB, Longphre M (2007) Effect of an interleukin-4 variant on late phase asthmatic response to allergen challenge in asthmatic patients: results of two phase 2a studies. Lancet 370(9596):1422–1431PubMed Wenzel S, Wilbraham D, Fuller R, Getz EB, Longphre M (2007) Effect of an interleukin-4 variant on late phase asthmatic response to allergen challenge in asthmatic patients: results of two phase 2a studies. Lancet 370(9596):1422–1431PubMed
5.
Zurück zum Zitat Scadding GK, Kariyawasam HH, Scadding G et al (2017) BSACI guideline for the diagnosis and management of allergic and non-allergic rhinitis. Clin Exp Allergy 47(7):856–889PubMed Scadding GK, Kariyawasam HH, Scadding G et al (2017) BSACI guideline for the diagnosis and management of allergic and non-allergic rhinitis. Clin Exp Allergy 47(7):856–889PubMed
6.
Zurück zum Zitat Bentley AM, Jacobson MR, Cumberworth V et al (1992) Immunohistology of the nasal mucosa in seasonal allergic rhinitis: increases in activated eosinophils and epithelial mast cells. J Allergy Clin Immunol 89(4):877–883PubMed Bentley AM, Jacobson MR, Cumberworth V et al (1992) Immunohistology of the nasal mucosa in seasonal allergic rhinitis: increases in activated eosinophils and epithelial mast cells. J Allergy Clin Immunol 89(4):877–883PubMed
7.
Zurück zum Zitat Beppu T, Ohta N, Gon S et al (1994) Eosinophil and eosinophil cationic protein in allergic rhinitis. Acta Otolaryngol 114(sup511):221–223 Beppu T, Ohta N, Gon S et al (1994) Eosinophil and eosinophil cationic protein in allergic rhinitis. Acta Otolaryngol 114(sup511):221–223
8.
Zurück zum Zitat Mullarkey MF, Hill JS, Webb DR (1980) Allergic and nonallergic rhinitis: their characterization with attention to the meaning of nasal eosinophilia. J Allergy Clin Immunol 65(2):122–126PubMed Mullarkey MF, Hill JS, Webb DR (1980) Allergic and nonallergic rhinitis: their characterization with attention to the meaning of nasal eosinophilia. J Allergy Clin Immunol 65(2):122–126PubMed
9.
Zurück zum Zitat Wilson AM, O’Byrne PM, Parameswaran K (2004) Leukotriene receptor antagonists for allergic rhinitis: a systematic review and meta-analysis. Am J Med 116(5):338–344PubMed Wilson AM, O’Byrne PM, Parameswaran K (2004) Leukotriene receptor antagonists for allergic rhinitis: a systematic review and meta-analysis. Am J Med 116(5):338–344PubMed
10.
Zurück zum Zitat Trangsrud AJ, Whitaker AL, Small RE (2002) Intranasal corticosteroids for allergic rhinitis. Pharmacother J Hum Pharmacol Drug Ther 22(11):1458–1467 Trangsrud AJ, Whitaker AL, Small RE (2002) Intranasal corticosteroids for allergic rhinitis. Pharmacother J Hum Pharmacol Drug Ther 22(11):1458–1467
11.
Zurück zum Zitat Stanbury RM, Graham EM (1998) Systemic corticosteroid therapy: side effects and their management. Br J Ophthalmol 82(6):704–708PubMedPubMedCentral Stanbury RM, Graham EM (1998) Systemic corticosteroid therapy: side effects and their management. Br J Ophthalmol 82(6):704–708PubMedPubMedCentral
12.
Zurück zum Zitat Durham SR, Penagos M (2016) Sublingual or subcutaneous immunotherapy for allergic rhinitis? J Allergy Clin Immunol 137(2):339–349PubMed Durham SR, Penagos M (2016) Sublingual or subcutaneous immunotherapy for allergic rhinitis? J Allergy Clin Immunol 137(2):339–349PubMed
13.
Zurück zum Zitat Penagos M, Durham SR (2019) Duration of allergen immunotherapy for inhalant allergy. Curr Opin Allergy Clin Immunol 19(6):594–605PubMed Penagos M, Durham SR (2019) Duration of allergen immunotherapy for inhalant allergy. Curr Opin Allergy Clin Immunol 19(6):594–605PubMed
14.
Zurück zum Zitat Musa F, Al-Ahmad M, Arifhodzic N, Al-Herz W (2017) Compliance with allergen immunotherapy and factors affecting compliance among patients with respiratory allergies. Hum Vaccin Immunother 13(3):514–517PubMed Musa F, Al-Ahmad M, Arifhodzic N, Al-Herz W (2017) Compliance with allergen immunotherapy and factors affecting compliance among patients with respiratory allergies. Hum Vaccin Immunother 13(3):514–517PubMed
15.
Zurück zum Zitat Epstein TG, Liss GM, Murphy-Berendts K, Bernstein DI (2016) Risk factors for fatal and nonfatal reactions to subcutaneous immunotherapy: national surveillance study on allergen immunotherapy (2008–2013). Ann Allergy Asthma Immunol 116(4):354–359PubMed Epstein TG, Liss GM, Murphy-Berendts K, Bernstein DI (2016) Risk factors for fatal and nonfatal reactions to subcutaneous immunotherapy: national surveillance study on allergen immunotherapy (2008–2013). Ann Allergy Asthma Immunol 116(4):354–359PubMed
16.
Zurück zum Zitat Calderón MA, Casale TB, Togias A, Bousquet J, Durham SR, Demoly P (2011) Allergen-specific immunotherapy for respiratory allergies: from meta-analysis to registration and beyond. J Allergy Clin Immunol 127(1):30–38PubMed Calderón MA, Casale TB, Togias A, Bousquet J, Durham SR, Demoly P (2011) Allergen-specific immunotherapy for respiratory allergies: from meta-analysis to registration and beyond. J Allergy Clin Immunol 127(1):30–38PubMed
17.
Zurück zum Zitat Peixoto CA, Silva BS (2014) Anti-inflammatory effects of diethylcarbamazine: a review. Eur J Pharmacol 734:35–41PubMed Peixoto CA, Silva BS (2014) Anti-inflammatory effects of diethylcarbamazine: a review. Eur J Pharmacol 734:35–41PubMed
18.
Zurück zum Zitat Masid-de-Brito D, Queto T, Gaspar-Elsas MI, Xavier-Elsas P (2014) Roles of 5-lipoxygenase and cysteinyl-leukotriene type 1 receptors in the hematological response to allergen challenge and its prevention by diethylcarbamazine in a murine model of asthma. Mediat Inflamm. https://doi.org/10.1155/2014/403970CrossRef Masid-de-Brito D, Queto T, Gaspar-Elsas MI, Xavier-Elsas P (2014) Roles of 5-lipoxygenase and cysteinyl-leukotriene type 1 receptors in the hematological response to allergen challenge and its prevention by diethylcarbamazine in a murine model of asthma. Mediat Inflamm. https://​doi.​org/​10.​1155/​2014/​403970CrossRef
19.
Zurück zum Zitat Juniper EF, Guyatt GH (1991) Development and testing of a new measure of health status for clinical trials in rhinoconjunctivitis. Clin Exp Allergy 21(1):77–83PubMed Juniper EF, Guyatt GH (1991) Development and testing of a new measure of health status for clinical trials in rhinoconjunctivitis. Clin Exp Allergy 21(1):77–83PubMed
20.
Zurück zum Zitat Samitas K, Carter A, Kariyawasam HH, Xanthou G (2018) Upper and lower airway remodelling mechanisms in asthma, allergic rhinitis and chronic rhinosinusitis: the one airway concept revisited. Allergy 73(5):993–1002PubMed Samitas K, Carter A, Kariyawasam HH, Xanthou G (2018) Upper and lower airway remodelling mechanisms in asthma, allergic rhinitis and chronic rhinosinusitis: the one airway concept revisited. Allergy 73(5):993–1002PubMed
21.
Zurück zum Zitat Bernstein DI, Schwartz G, Bernstein JA (2016) Allergic rhinitis: mechanisms and treatment. Immunol Allergy Clin N Am 36(2):261–278 Bernstein DI, Schwartz G, Bernstein JA (2016) Allergic rhinitis: mechanisms and treatment. Immunol Allergy Clin N Am 36(2):261–278
22.
Zurück zum Zitat Ottesen EA (1985) Efficacy of diethylcarbamazine in eradicating infection with lymphatic-dwelling filariae in humans. Rev Infect Dis 7(3):341–356PubMed Ottesen EA (1985) Efficacy of diethylcarbamazine in eradicating infection with lymphatic-dwelling filariae in humans. Rev Infect Dis 7(3):341–356PubMed
23.
24.
Zurück zum Zitat Florêncio MS, Saraiva KL, Peixoto CA (2005) The effects of diethylcarbamazine on the ultrastructure of lung cells in vivo. Tissue Cell 37(3):241–246PubMed Florêncio MS, Saraiva KL, Peixoto CA (2005) The effects of diethylcarbamazine on the ultrastructure of lung cells in vivo. Tissue Cell 37(3):241–246PubMed
25.
Zurück zum Zitat Segoviano-Ramirez JC, Lopez-Altamirano DF, Garcia-Juarez J, Aguirre-Garza JE, Cárdenas-Estrada E, Ancer-Rodriguez J (2020) The diethylcarbamazine delays and decreases the netosis of polymorphonuclear cells of humans with DM Type 2. J Diabetes Res 2020:4827641PubMedPubMedCentral Segoviano-Ramirez JC, Lopez-Altamirano DF, Garcia-Juarez J, Aguirre-Garza JE, Cárdenas-Estrada E, Ancer-Rodriguez J (2020) The diethylcarbamazine delays and decreases the netosis of polymorphonuclear cells of humans with DM Type 2. J Diabetes Res 2020:4827641PubMedPubMedCentral
26.
Zurück zum Zitat El AE, Sokar SS, Shebl AM, Mohamed DZ (2017) Antifibrotic effect of diethylcarbamazine combined with hesperidin against ethanol induced liver fibrosis in rats. Biomed Pharmacother 89:1196–1206 El AE, Sokar SS, Shebl AM, Mohamed DZ (2017) Antifibrotic effect of diethylcarbamazine combined with hesperidin against ethanol induced liver fibrosis in rats. Biomed Pharmacother 89:1196–1206
27.
Zurück zum Zitat Jia G, Zao M, Liu X (2017) Protective effect of diethylcarbamazine inhibits NF-κB activation in isoproterenol-induced acute myocardial infarction rat model through the PARP pathway. Mol Med Rep 16(2):1596–1602PubMed Jia G, Zao M, Liu X (2017) Protective effect of diethylcarbamazine inhibits NF-κB activation in isoproterenol-induced acute myocardial infarction rat model through the PARP pathway. Mol Med Rep 16(2):1596–1602PubMed
28.
Zurück zum Zitat de França ME, Rocha SW, Oliveira WH et al (2018) Diethylcarbamazine attenuates the expression of pro-fibrogenic markers and hepatic stellate cells activation in carbon tetrachloride-induced liver fibrosis. Inflammopharmacology 26(2):599–609PubMed de França ME, Rocha SW, Oliveira WH et al (2018) Diethylcarbamazine attenuates the expression of pro-fibrogenic markers and hepatic stellate cells activation in carbon tetrachloride-induced liver fibrosis. Inflammopharmacology 26(2):599–609PubMed
29.
Zurück zum Zitat Farzipour S, Amiri FT, Mihandoust E et al (2020) Radioprotective effect of diethylcarbamazine on radiation-induced acute lung injury and oxidative stress in mice. J Bioenerg Biomembr 52(1):39–46PubMed Farzipour S, Amiri FT, Mihandoust E et al (2020) Radioprotective effect of diethylcarbamazine on radiation-induced acute lung injury and oxidative stress in mice. J Bioenerg Biomembr 52(1):39–46PubMed
30.
Zurück zum Zitat Ribeiro EL, Fragoso IT, dos Santos Gomes FO et al (2017) Diethylcarbamazine: A potential treatment drug for pulmonary hypertension? Toxicol Appl Pharmacol 333:92–99PubMed Ribeiro EL, Fragoso IT, dos Santos Gomes FO et al (2017) Diethylcarbamazine: A potential treatment drug for pulmonary hypertension? Toxicol Appl Pharmacol 333:92–99PubMed
31.
Zurück zum Zitat Medina-De la Garza CE, Guerrero-Ramírez G, García-Hernández M et al (2012) Immunomodulatory activity of diethylcarbamazine on humoral, cellular cytokine response and respiratory burst in BALB/c mice. Immunopharmacol Immunotoxicol 34(3):477–483PubMed Medina-De la Garza CE, Guerrero-Ramírez G, García-Hernández M et al (2012) Immunomodulatory activity of diethylcarbamazine on humoral, cellular cytokine response and respiratory burst in BALB/c mice. Immunopharmacol Immunotoxicol 34(3):477–483PubMed
32.
Zurück zum Zitat Masid-de-Brito D, Vieira BM, de Souza CC, Silva F, Gaspar-Elsas MI, Xavier-Elsas P (2020) Allergen challenge-induced changes in bone-marrow responses to leukotriene D4, nonsteroidal anti-inflammatory drugs and cytokines. Immunopharmacol Immunotoxicol 42(3):199–210PubMed Masid-de-Brito D, Vieira BM, de Souza CC, Silva F, Gaspar-Elsas MI, Xavier-Elsas P (2020) Allergen challenge-induced changes in bone-marrow responses to leukotriene D4, nonsteroidal anti-inflammatory drugs and cytokines. Immunopharmacol Immunotoxicol 42(3):199–210PubMed
34.
Zurück zum Zitat Liu W, Liu S, Verma M et al (2017) Mechanism of TH2/TH17-predominant and neutrophilic TH2/TH17-low subtypes of asthma. J Allergy Clin Immunol 139(5):1548–1558PubMed Liu W, Liu S, Verma M et al (2017) Mechanism of TH2/TH17-predominant and neutrophilic TH2/TH17-low subtypes of asthma. J Allergy Clin Immunol 139(5):1548–1558PubMed
35.
Zurück zum Zitat Suphioglu C, Singh MB, Taylor P et al (1992) Mechanism of grass-pollen-induced asthma. Lancet 339(8793):569–572PubMed Suphioglu C, Singh MB, Taylor P et al (1992) Mechanism of grass-pollen-induced asthma. Lancet 339(8793):569–572PubMed
36.
Zurück zum Zitat Cockcroft DW (1983) Mechanism of perennial allergic asthma. Lancet 322(8344):253–256 Cockcroft DW (1983) Mechanism of perennial allergic asthma. Lancet 322(8344):253–256
37.
Zurück zum Zitat Flint KC, Leung KB, Hudspith BN, Brostoff J, Pearce FL, Johnson NM (1985) Bronchoalveolar mast cells in extrinsic asthma: a mechanism for the initiation of antigen specific bronchoconstriction. Br Med J 291(6500):923–926 Flint KC, Leung KB, Hudspith BN, Brostoff J, Pearce FL, Johnson NM (1985) Bronchoalveolar mast cells in extrinsic asthma: a mechanism for the initiation of antigen specific bronchoconstriction. Br Med J 291(6500):923–926
38.
Zurück zum Zitat McFadden ER Jr, Luparello TH, Lyons HA, Bleecker E (1969) The mechanism of action of suggestion in the induction of acute asthma attacks. Psychosom Med 31(2):134–143PubMed McFadden ER Jr, Luparello TH, Lyons HA, Bleecker E (1969) The mechanism of action of suggestion in the induction of acute asthma attacks. Psychosom Med 31(2):134–143PubMed
39.
Zurück zum Zitat Parnes SM (2002) The role of leukotriene inhibitors in allergic rhinitis and paranasal sinusitis. Curr Allergy Asthma Rep 2(3):239–244PubMed Parnes SM (2002) The role of leukotriene inhibitors in allergic rhinitis and paranasal sinusitis. Curr Allergy Asthma Rep 2(3):239–244PubMed
40.
Zurück zum Zitat Denburg JA, Gauvreau GM (2005) Hemopoietic progenitors: the role of eosinophil/basophil progenitors in allergic airway inflammation. Expert Rev Clin Immunol 1(1):87–101PubMed Denburg JA, Gauvreau GM (2005) Hemopoietic progenitors: the role of eosinophil/basophil progenitors in allergic airway inflammation. Expert Rev Clin Immunol 1(1):87–101PubMed
41.
Zurück zum Zitat Queto T, Xavier-Elsas P, Gardel MA et al (2010) Inducible nitric oxide synthase/CD95L-dependent suppression of pulmonary and bone marrow eosinophilia by diethylcarbamazine. Am J Respir Crit Care Med 181(5):429–437PubMed Queto T, Xavier-Elsas P, Gardel MA et al (2010) Inducible nitric oxide synthase/CD95L-dependent suppression of pulmonary and bone marrow eosinophilia by diethylcarbamazine. Am J Respir Crit Care Med 181(5):429–437PubMed
42.
Zurück zum Zitat Vijayan VK, Rao KK, Sankaran K, Venkatesan P, Prabhakar R (1991) Tropical eosinophilia: clinical and physiological response to diethylcarbamazine. Respir Med 85(1):17–20PubMed Vijayan VK, Rao KK, Sankaran K, Venkatesan P, Prabhakar R (1991) Tropical eosinophilia: clinical and physiological response to diethylcarbamazine. Respir Med 85(1):17–20PubMed
43.
Zurück zum Zitat Snidvongs K, Seresirikachorn K, Khattiyawittayakun L, Chitsuthipakorn W (2017) Sedative effects of levocetirizine: a systematic review and meta-analysis of randomized controlled studies. Drugs 77(2):175–186PubMed Snidvongs K, Seresirikachorn K, Khattiyawittayakun L, Chitsuthipakorn W (2017) Sedative effects of levocetirizine: a systematic review and meta-analysis of randomized controlled studies. Drugs 77(2):175–186PubMed
44.
Zurück zum Zitat Layton D, Wilton L, Boshier A, Cornelius V, Harris S, Shakir SA (2006) Comparison of the risk of drowsiness and sedation between levocetirizine and desloratadine. Drug saf 29(10):897–909PubMed Layton D, Wilton L, Boshier A, Cornelius V, Harris S, Shakir SA (2006) Comparison of the risk of drowsiness and sedation between levocetirizine and desloratadine. Drug saf 29(10):897–909PubMed
45.
Zurück zum Zitat Hay J, Jhaveri M, Tangirala M, Kaliner M (2009) Cost and resource utilization comparisons of second-generation antihistamines versus montelukast for allergic rhinitis treatment. Allergy Asthma Proc 30(6):634–642PubMed Hay J, Jhaveri M, Tangirala M, Kaliner M (2009) Cost and resource utilization comparisons of second-generation antihistamines versus montelukast for allergic rhinitis treatment. Allergy Asthma Proc 30(6):634–642PubMed
46.
Zurück zum Zitat Goodman MJ, Jhaveri M, Saverno K, Meyer K, Nightengale B (2008) Cost-effectiveness of second-generation antihistamines and montelukast in relieving allergic rhinitis nasal symptoms. Am Health Drug Benefits 1(8):26–34PubMedPubMedCentral Goodman MJ, Jhaveri M, Saverno K, Meyer K, Nightengale B (2008) Cost-effectiveness of second-generation antihistamines and montelukast in relieving allergic rhinitis nasal symptoms. Am Health Drug Benefits 1(8):26–34PubMedPubMedCentral
47.
Zurück zum Zitat Ciprandi G, Cirillo I, Vizzaccaro A, Tosca MA (2004) Levocetirizine improves nasal obstruction and modulates cytokine pattern in patients with seasonal allergic rhinitis: a pilot study. Clin Exp Allergy 34(6):958–964PubMed Ciprandi G, Cirillo I, Vizzaccaro A, Tosca MA (2004) Levocetirizine improves nasal obstruction and modulates cytokine pattern in patients with seasonal allergic rhinitis: a pilot study. Clin Exp Allergy 34(6):958–964PubMed
48.
Zurück zum Zitat Bachert C (2005) Levocetirizine: a modern H1-antihistamine for the treatment of allergic rhinitis. Expert Rev Clin Immunol 1(4):495–510PubMed Bachert C (2005) Levocetirizine: a modern H1-antihistamine for the treatment of allergic rhinitis. Expert Rev Clin Immunol 1(4):495–510PubMed
49.
Zurück zum Zitat Klimek L (2005) Potential of levocetirizine in the relief of nasal congestion. Int J Clin Pract 59(6):721–729PubMed Klimek L (2005) Potential of levocetirizine in the relief of nasal congestion. Int J Clin Pract 59(6):721–729PubMed
50.
Zurück zum Zitat Ciebiada M, Górska-Ciebiada M, DuBuske LM, Górski P (2006) Montelukast with desloratadine or levocetirizine for the treatment of persistent allergic rhinitis. Ann Allergy Asthma Immunol 97(5):664–671PubMed Ciebiada M, Górska-Ciebiada M, DuBuske LM, Górski P (2006) Montelukast with desloratadine or levocetirizine for the treatment of persistent allergic rhinitis. Ann Allergy Asthma Immunol 97(5):664–671PubMed
Metadaten
Titel
Efficacy and Safety of Diethylcarbamazine in Treatment of Allergic Rhinitis: A Double Blind Randomised Controlled Trial
verfasst von
S. Mohana Karthikeyan
G. N. Nikisha
Publikationsdatum
31.10.2020
Verlag
Springer India
Erschienen in
Indian Journal of Otolaryngology and Head & Neck Surgery / Ausgabe Sonderheft 2/2022
Print ISSN: 2231-3796
Elektronische ISSN: 0973-7707
DOI
https://doi.org/10.1007/s12070-020-02249-2

Neu im Fachgebiet HNO

Ab sofort gelten die neuen Verordnungsausnahmen für Lipidsenker

Freie Fahrt für Lipidsenker? Das nicht, doch mit niedrigerem Schwellenwert fürs Infarktrisiko und neuen Indikationen hat der G-BA die Verordnungs-Handbremse ein gutes Stück weit gelockert.

Lagerungsschwindel hält trotz Manöver an: Was steckt dahinter?

Ob sich ein benigner paroxysmaler Lagerungsschwindel erfolgreich behandeln lässt, könnte einem chinesischen Team zufolge auch von psychischen Faktoren abhängen.

Zi veröffentlicht Ranking zur Fehleranfälligkeit gängiger Praxis-EDV

Welches Praxisverwaltungssystem macht am wenigsten Probleme? Das Zi dokumentiert jetzt detaillierte Produktbewertungen zu 17 konkreten Anwendungssituationen.

Weiterbildung: So kommen Sie an die Facharzt-Förderung

  • 02.02.2025
  • EBM
  • Nachrichten

Wer in Praxis oder MVZ junge Kolleginnen und Kollegen zum Facharzt weiterbildet, muss nicht allein auf den Kosten sitzen bleiben; KV und Kostenträger fördern die Weiterbildung. Pünktlich zum Januar wurde der Betrag je Vollzeitstelle auf 5.800 Euro erhöht. Mitunter gibt es weitere Zuschläge. Die wichtigsten Fragen und Antworten zum Zuschuss.

Update HNO

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert – ganz bequem per eMail.